• 21 Jan 19

Shield Therapeutics' Feraccru drug 'a potential game-changer' - Capital Network Analyst

Shield Therapeutics' Feraccru drug 'a potential game-changer' - Capital Network Analyst

Shield Therapeutics Plc | STX | 2.5 0 0%

    • 228 views

 

Capital Network analyst Riccardo Lowi discusses Shield Therapeutics PLC’s (LON:STX) lead asset Feraccru - a novel and highly differentiated iron formulation, for oral administration, indicated for the treatment of iron deficiency. US regulators have set a target date for a decision on whether or not to approve it by 27 July 2019.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Shield Therapeutics Eyes Cash Flow Positive Target by 2025

Companies: Shield Therapeutics Plc

Executive interview - Shield Therapeutics

Companies: Shield Therapeutics Plc

Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst

Companies: Shield Therapeutics Plc

Shield Therapeutics makes a profit and is 'cash positive' during first-half of the year

Companies: Shield Therapeutics Plc

Shield Therapeautics "couldn't be more pleased" with Viatris collaboration

Companies: Shield Therapeutics Plc

Shield Therapeutics CEO says reanalysis of key study has shown Feraccru to be 'credible alternative'

Companies: Shield Therapeutics Plc

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top